Pembrolizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pembrolizumab: From Advanced Melanoma to Gingival Fibromatosis
One-Sentence Summary
Pembrolizumab (Keytruda®) is a PD-1 immune checkpoint inhibitor first approved for advanced/unresectable melanoma and since expanded to more than a dozen solid and hematologic cancers. The TxGNN model’s top-ranked repurposing candidate in this batch is Gingival Fibromatosis (prediction score 99.40%), but this specific prediction currently has 0 clinical trials and 0 publications supporting it — it is a model-only signal (Evidence Level L5) that the model’s own rationale flags as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Advanced/unresectable Melanoma (first global approval, 2014); since expanded to NSCLC, HNSCC, classical Hodgkin lymphoma, urothelial carcinoma, MSI-H/dMMR solid tumors, and others |
| Predicted New Indication | Gingival Fibromatosis (fibromatosis, gingival) |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Pembrolizumab’s confirmed mechanism (drawn from the pharmacology data in this evidence pack, since a formal DrugBank MOA field is still pending) is a humanized IgG4 monoclonal antibody that blocks PD-1 (CD279) on T-cells, preventing PD-1/PD-L1 mediated immune evasion by tumor cells. This mechanism underlies its efficacy across a wide range of malignancies with high tumor mutational burden or PD-L1 expression — melanoma, NSCLC, head and neck squamous cell carcinoma, MSI-H/dMMR tumors, and more.
Gingival fibromatosis, however, is a benign, non-neoplastic overgrowth of gingival connective tissue, typically driven by fibroblast proliferation (hereditary or drug-induced, e.g., by phenytoin, cyclosporine, or calcium channel blockers) rather than by immune evasion or checkpoint dysregulation. There is no established tumor-immunology pathway connecting PD-1 blockade to fibroblast-driven connective tissue overgrowth.
Consequently, the model’s own generated rationale for this candidate explicitly states that gingival fibromatosis is a benign connective-tissue disorder — not an immune-evasive or neoplastic lesion — and that there is no plausible mechanistic link to PD-1 inhibition. With zero clinical trials and zero literature records retrieved, this prediction should be treated as a low-confidence embedding artifact rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Pembrolizumab has no registered licenses in India in this dataset (0 total licenses; market status: Not Marketed). No product/dosage-form/indication records are available to tabulate.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-PD-1 immune checkpoint inhibitor monoclonal antibody) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Low — checkpoint inhibitors act via immune activation rather than direct cytotoxicity; the dominant toxicity class is immune-related adverse events (irAEs) rather than bone marrow suppression |
| Emetogenicity Classification | Low |
| Monitoring Items | Thyroid function, liver function, renal function, pulmonary status (pneumonitis), skin, and signs of immune-related adverse events (colitis, hepatitis, endocrinopathy, myocarditis/myositis/myasthenia gravis, neurologic irAEs) — per general checkpoint-inhibitor toxicity literature retrieved in this pack |
| Handling Protection | As a biologic monoclonal antibody administered by IV/SC infusion, pembrolizumab does not require conventional hazardous cytotoxic drug handling precautions (e.g., NIOSH cytotoxic PPE); standard biologic infusion handling protocols apply |
Safety Considerations
Drug Interactions (13 total on file):
- Major: Lenalidomide, Pomalidomide, Thalidomide
- Moderate: Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Prednisolone, Prednisone, Methylprednisolone, Deflazacort
(Systemic corticosteroids may blunt immunotherapy efficacy via immunosuppression; concomitant IMiDs carry major-level interaction flags.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Gingival Fibromatosis) has no clinical trial or literature support and is explicitly flagged by the model’s own rationale as mechanistically implausible — it is best interpreted as an embedding-based ontology artifact rather than a genuine signal. Regulatory safety documentation (warnings/contraindications) is also incomplete, blocking a full safety assessment.
To proceed, the following is needed:
- TFDA/India label warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism-of-action record via DrugBank API
- Re-review of disease-ontology mapping across this candidate batch — several other ranked candidates (e.g., “lung benign neoplasm,” “lung germ cell tumor”) show clinical trial/literature evidence that actually pertains to NSCLC rather than the labeled disease, suggesting systematic ontology-neighbor mismatches worth investigating before any candidate in this batch advances past Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.